|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Operating expenses | |||||
| Operating expenses | |||||
| Selling, general and administrative | |||||
| Research, product development and regulatory | |||||
| Bargain purchase gain on business acquisition | |||||
| Product liability claims | |||||
| Transformation | |||||
| Asset impairment | |||||
| Gain from sale of assets | |||||
| Operating (loss) income | |||||
| Change in fair value of equity investments, net | |||||
| Other income | |||||
| Interest and other interest expenses, net | |||||
| (Loss) income before provision for income taxes | |||||
| Provision for income taxes | |||||
| Income before loss on equity method investment | |||||
| Loss from equity method investment | |||||
| Net (loss) income | |||||
| (Losses) earnings per common share-basic | |||||
| (Losses) earnings per common share-assuming dilution | |||||
| Weighted average shares outstanding—basic | |||||
| Weighted average shares outstanding—assuming dilution |
Loading...
